BlueWillow Biologics Awarded Grant for Chlamydia Vaccine Development

BlueWillow Biologics Awarded Grant for Chlamydia Vaccine Development – 9/26/2018

BlueWillow Biologics® has been awarded a NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax® vaccine for the prevention of chlamydia. There are more than 131 million new chlamydia infections worldwide each year and no approved vaccine currently exists to prevent the infection.

news,